PEGETRON 200 MG
RIBAVIRIN : 200 MG PEGINTERFERON ALFA-2B : 100 MCG / 0.5 ML · DIN 02254603 · MERCK CANADA INC
Health Canada status: CANCELLED POST MARKET
What is PEGETRON?
PEGETRON 200 MG contains RIBAVIRIN : 200 MG PEGINTERFERON ALFA-2B : 100 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02254603, held by MERCK CANADA INC, supplied as CAPSULE ; POWDER FOR SOLUTION for SUBCUTANEOUS ; ORAL administration. Health Canada currently lists it as cancelled post market, status dated 05-Oct-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PEGETRON used for?
Treatment of chronic hepatitis C in adults (>= 18 years) with compensated liver disease who are HCV-RNA positive, including treatment-naive patients or those who failed prior interferon therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02254603 |
|---|---|
| Brand name | PEGETRON |
| Generic / active ingredient | RIBAVIRIN : 200 MG PEGINTERFERON ALFA-2B : 100 MCG / 0.5 ML |
| Manufacturer | MERCK CANADA INC |
| Strength | 200 MG |
| Dosage form | CAPSULE ; POWDER FOR SOLUTION |
| Route of administration | SUBCUTANEOUS ; ORAL |
| Schedule | Prescription |
| ATC code | L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS |
| AHFS class | 08:18.32 ; 08:18.20 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 05-Oct-2017 |
| Original market date | 2004-09-17 00:00:00 |
How is it administered?
Combination therapy: ribavirin capsules taken orally and peginterferon alfa-2b administered subcutaneously once weekly. Dose modifications required for hematologic toxicity or renal/cardiac issues.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided summary text, though the section is listed in the Table of Contents (page 38).
How is it supplied?
Ribavirin 200 mg capsules; Peginterferon alfa-2b in vials (50, 150 mcg) or CLEARCLICK Single Dose Delivery System (80, 100, 120, 150 mcg).
Contraindications
Hypersensitivity to interferons/ribavirin; pregnancy and male partners of pregnant women; autoimmune hepatitis; severe psychiatric disorders; thyroid abnormalities; renal dysfunction (CrCl < 50 mL/min).
Warnings and precautions
Serious Warnings: May cause or aggravate fatal neuropsychiatric, autoimmune, ischemic, and infectious disorders. Monitor for depression, suicidal behavior, and hemolytic anemia.
What can be used instead?
Other Canadian products sharing ATC code L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS. 0 of 15 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PEGETRON | 100 MCG / 0.5 ML | CAPSULE ; POWDER FOR SOLUTION | MERCK CANADA INC | CANCELLED POST MARKET | DIN 02246028 |
| PEGETRON | 150 MCG / 0.5 ML | CAPSULE ; POWDER FOR SOLUTION | MERCK CANADA INC | CANCELLED POST MARKET | DIN 02246030 |
| PEGETRON | 200 MG | POWDER FOR SOLUTION ; CAPSULE | MERCK CANADA INC | CANCELLED POST MARKET | DIN 02246027 |
| PEGETRON | 200 MG | CAPSULE ; POWDER FOR SOLUTION | MERCK CANADA INC | CANCELLED POST MARKET | DIN 02246029 |
| PEGETRON | 200 MG | CAPSULE ; POWDER FOR SOLUTION | MERCK CANADA INC | CANCELLED POST MARKET | DIN 02254638 |
| PEGETRON | 200 MG | CAPSULE ; POWDER FOR SOLUTION | MERCK CANADA INC | CANCELLED POST MARKET | DIN 02254646 |
| PEGETRON | 50 MCG / 0.5 ML | POWDER FOR SOLUTION ; CAPSULE | MERCK CANADA INC | CANCELLED POST MARKET | DIN 02246026 |
| PEGETRON | 80 MCG / 0.5 ML | POWDER FOR SOLUTION ; CAPSULE | MERCK CANADA INC | CANCELLED POST MARKET | DIN 02254581 |
| REBETRON READY TO USE SOLUTION (ALBUMIN(HUMAN)FREE) (6000000 IU/ML AND 200MG CAPSULES) | 200 MG | KIT ; CAPSULE ; LIQUID | SCHERING-PLOUGH CANADA INC | CANCELLED POST MARKET | DIN 02239730 |
| REBETRON SOLUTION (ALBUMIN (HUMAN) FREE) (18 MIU MULTI-DOSE PEN / 200MG CAPSULES) | 200 MG | KIT ; LIQUID ; CAPSULE | SCHERING-PLOUGH CANADA INC | CANCELLED POST MARKET | DIN 02241159 |
Who else supplies PEGINTERFERON ALFA-2B, COMBINATIONS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PEGINTERFERON ALFA-2B, COMBINATIONS appears in 70 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.